 | • レポートコード：MRC2-11QY11371 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は慢性閉塞性肺疾患（COPD）のグローバル市場について調査・分析したレポートです。種類別（気管支拡張薬、糖質コルチコイド、その他）市場規模、用途別（予防、診断、治療）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別慢性閉塞性肺疾患（COPD）の競争状況、市場シェア ・世界の慢性閉塞性肺疾患（COPD）市場：種類別市場規模 2015年-2020年（気管支拡張薬、糖質コルチコイド、その他） ・世界の慢性閉塞性肺疾患（COPD）市場：種類別市場規模予測 2021年-2026年（気管支拡張薬、糖質コルチコイド、その他） ・世界の慢性閉塞性肺疾患（COPD）市場：用途別市場規模 2015年-2020年（予防、診断、治療） ・世界の慢性閉塞性肺疾患（COPD）市場：用途別市場規模予測 2021年-2026年（予防、診断、治療） ・北米の慢性閉塞性肺疾患（COPD）市場分析：米国、カナダ ・ヨーロッパの慢性閉塞性肺疾患（COPD）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの慢性閉塞性肺疾患（COPD）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の慢性閉塞性肺疾患（COPD）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの慢性閉塞性肺疾患（COPD）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、GSK、MSD、Sunovion、Novartis、Roche Group、Pfizer、Jubilant Pharma Limited、Almirall、Horizon Pharma、Boehringer Ingelheim ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eventually everyday activities, such as walking or getting dressed, become difficult .Chronic bronchitis and emphysema are older terms used for different types of COPD.
Globally the market for COPD is increasing rapidly. The major factor that derives the growth of COPD is the increasing growth in smoking in adults. Furthermore increasing pollution in the environment and increasing asthma patients are increasing the growth of COPD market.
Market Analysis and Insights: Global Chronic Obstructive Pulmonary Disease Market
The global Chronic Obstructive Pulmonary Disease market size is projected to reach US$ 4113.4 million by 2026, from US$ 3998.2 million in 2020, at a CAGR of 2.7%% during 2021-2026.
Global Chronic Obstructive Pulmonary Disease Scope and Market Size
Chronic Obstructive Pulmonary Disease market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chronic Obstructive Pulmonary Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
AstraZeneca
GSK
MSD
Sunovion
Novartis
Roche Group
Pfizer
Jubilant Pharma Limited
Almirall
Horizon Pharma
Boehringer Ingelheim
Market segment by Type, the product can be split into
Bronchodilators
Glucocorticoids
Other
Market segment by Application, split into
Prevention
Diagnostic
Treatment
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disease Revenue
1.4 Market by Type
1.4.1 Global Chronic Obstructive Pulmonary Disease Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Bronchodilators
1.4.3 Glucocorticoids
1.4.4 Other
1.5 Market by Application
1.5.1 Global Chronic Obstructive Pulmonary Disease Market Share by Application: 2020 VS 2026
1.5.2 Prevention
1.5.3 Diagnostic
1.5.4 Treatment
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Chronic Obstructive Pulmonary Disease Market Perspective (2015-2026)
2.2 Global Chronic Obstructive Pulmonary Disease Growth Trends by Regions
2.2.1 Chronic Obstructive Pulmonary Disease Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Chronic Obstructive Pulmonary Disease Historic Market Share by Regions (2015-2020)
2.2.3 Chronic Obstructive Pulmonary Disease Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Chronic Obstructive Pulmonary Disease Market Growth Strategy
2.3.6 Primary Interviews with Key Chronic Obstructive Pulmonary Disease Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Chronic Obstructive Pulmonary Disease Players by Market Size
3.1.1 Global Top Chronic Obstructive Pulmonary Disease Players by Revenue (2015-2020)
3.1.2 Global Chronic Obstructive Pulmonary Disease Revenue Market Share by Players (2015-2020)
3.1.3 Global Chronic Obstructive Pulmonary Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Chronic Obstructive Pulmonary Disease Market Concentration Ratio
3.2.1 Global Chronic Obstructive Pulmonary Disease Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disease Revenue in 2019
3.3 Chronic Obstructive Pulmonary Disease Key Players Head office and Area Served
3.4 Key Players Chronic Obstructive Pulmonary Disease Product Solution and Service
3.5 Date of Enter into Chronic Obstructive Pulmonary Disease Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Chronic Obstructive Pulmonary Disease Historic Market Size by Type (2015-2020)
4.2 Global Chronic Obstructive Pulmonary Disease Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020)
5.2 Global Chronic Obstructive Pulmonary Disease Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Chronic Obstructive Pulmonary Disease Market Size (2015-2020)
6.2 Chronic Obstructive Pulmonary Disease Key Players in North America (2019-2020)
6.3 North America Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020)
6.4 North America Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020)
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disease Market Size (2015-2020)
7.2 Chronic Obstructive Pulmonary Disease Key Players in Europe (2019-2020)
7.3 Europe Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020)
7.4 Europe Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020)
8 China
8.1 China Chronic Obstructive Pulmonary Disease Market Size (2015-2020)
8.2 Chronic Obstructive Pulmonary Disease Key Players in China (2019-2020)
8.3 China Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020)
8.4 China Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020)
9 Japan
9.1 Japan Chronic Obstructive Pulmonary Disease Market Size (2015-2020)
9.2 Chronic Obstructive Pulmonary Disease Key Players in Japan (2019-2020)
9.3 Japan Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020)
9.4 Japan Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Chronic Obstructive Pulmonary Disease Market Size (2015-2020)
10.2 Chronic Obstructive Pulmonary Disease Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020)
10.4 Southeast Asia Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020)
11 India
11.1 India Chronic Obstructive Pulmonary Disease Market Size (2015-2020)
11.2 Chronic Obstructive Pulmonary Disease Key Players in India (2019-2020)
11.3 India Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020)
11.4 India Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Chronic Obstructive Pulmonary Disease Market Size (2015-2020)
12.2 Chronic Obstructive Pulmonary Disease Key Players in Central & South America (2019-2020)
12.3 Central & South America Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020)
12.4 Central & South America Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca Chronic Obstructive Pulmonary Disease Introduction
13.1.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 GSK
13.2.1 GSK Company Details
13.2.2 GSK Business Overview
13.2.3 GSK Chronic Obstructive Pulmonary Disease Introduction
13.2.4 GSK Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020)
13.2.5 GSK Recent Development
13.3 MSD
13.3.1 MSD Company Details
13.3.2 MSD Business Overview
13.3.3 MSD Chronic Obstructive Pulmonary Disease Introduction
13.3.4 MSD Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020)
13.3.5 MSD Recent Development
13.4 Sunovion
13.4.1 Sunovion Company Details
13.4.2 Sunovion Business Overview
13.4.3 Sunovion Chronic Obstructive Pulmonary Disease Introduction
13.4.4 Sunovion Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020)
13.4.5 Sunovion Recent Development
13.5 Novartis
13.5.1 Novartis Company Details
13.5.2 Novartis Business Overview
13.5.3 Novartis Chronic Obstructive Pulmonary Disease Introduction
13.5.4 Novartis Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020)
13.5.5 Novartis Recent Development
13.6 Roche Group
13.6.1 Roche Group Company Details
13.6.2 Roche Group Business Overview
13.6.3 Roche Group Chronic Obstructive Pulmonary Disease Introduction
13.6.4 Roche Group Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020)
13.6.5 Roche Group Recent Development
13.7 Pfizer
13.7.1 Pfizer Company Details
13.7.2 Pfizer Business Overview
13.7.3 Pfizer Chronic Obstructive Pulmonary Disease Introduction
13.7.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020)
13.7.5 Pfizer Recent Development
13.8 Jubilant Pharma Limited
13.8.1 Jubilant Pharma Limited Company Details
13.8.2 Jubilant Pharma Limited Business Overview
13.8.3 Jubilant Pharma Limited Chronic Obstructive Pulmonary Disease Introduction
13.8.4 Jubilant Pharma Limited Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020)
13.8.5 Jubilant Pharma Limited Recent Development
13.9 Almirall
13.9.1 Almirall Company Details
13.9.2 Almirall Business Overview
13.9.3 Almirall Chronic Obstructive Pulmonary Disease Introduction
13.9.4 Almirall Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020)
13.9.5 Almirall Recent Development
13.10 Horizon Pharma
13.10.1 Horizon Pharma Company Details
13.10.2 Horizon Pharma Business Overview
13.10.3 Horizon Pharma Chronic Obstructive Pulmonary Disease Introduction
13.10.4 Horizon Pharma Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020)
13.10.5 Horizon Pharma Recent Development
13.11 Boehringer Ingelheim
10.11.1 Boehringer Ingelheim Company Details
10.11.2 Boehringer Ingelheim Business Overview
10.11.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Introduction
10.11.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020)
10.11.5 Boehringer Ingelheim Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Chronic Obstructive Pulmonary Disease Key Market Segments
Table 2. Key Players Covered: Ranking by Chronic Obstructive Pulmonary Disease Revenue
Table 3. Ranking of Global Top Chronic Obstructive Pulmonary Disease Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Chronic Obstructive Pulmonary Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Bronchodilators
Table 6. Key Players of Glucocorticoids
Table 7. Key Players of Other
Table 8. Global Chronic Obstructive Pulmonary Disease Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Chronic Obstructive Pulmonary Disease Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Chronic Obstructive Pulmonary Disease Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Chronic Obstructive Pulmonary Disease Market Share by Regions (2015-2020)
Table 12. Global Chronic Obstructive Pulmonary Disease Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Chronic Obstructive Pulmonary Disease Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Chronic Obstructive Pulmonary Disease Market Growth Strategy
Table 18. Main Points Interviewed from Key Chronic Obstructive Pulmonary Disease Players
Table 19. Global Chronic Obstructive Pulmonary Disease Revenue by Players (2015-2020) (Million US$)
Table 20. Global Chronic Obstructive Pulmonary Disease Market Share by Players (2015-2020)
Table 21. Global Top Chronic Obstructive Pulmonary Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Obstructive Pulmonary Disease as of 2019)
Table 22. Global Chronic Obstructive Pulmonary Disease by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Chronic Obstructive Pulmonary Disease Product Solution and Service
Table 25. Date of Enter into Chronic Obstructive Pulmonary Disease Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020) (Million US$)
Table 28. Global Chronic Obstructive Pulmonary Disease Market Size Share by Type (2015-2020)
Table 29. Global Chronic Obstructive Pulmonary Disease Revenue Market Share by Type (2021-2026)
Table 30. Global Chronic Obstructive Pulmonary Disease Market Size Share by Application (2015-2020)
Table 31. Global Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020) (Million US$)
Table 32. Global Chronic Obstructive Pulmonary Disease Market Size Share by Application (2021-2026)
Table 33. North America Key Players Chronic Obstructive Pulmonary Disease Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Chronic Obstructive Pulmonary Disease Market Share (2019-2020)
Table 35. North America Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020) (Million US$)
Table 36. North America Chronic Obstructive Pulmonary Disease Market Share by Type (2015-2020)
Table 37. North America Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020) (Million US$)
Table 38. North America Chronic Obstructive Pulmonary Disease Market Share by Application (2015-2020)
Table 39. Europe Key Players Chronic Obstructive Pulmonary Disease Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Chronic Obstructive Pulmonary Disease Market Share (2019-2020)
Table 41. Europe Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Chronic Obstructive Pulmonary Disease Market Share by Type (2015-2020)
Table 43. Europe Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Chronic Obstructive Pulmonary Disease Market Share by Application (2015-2020)
Table 45. China Key Players Chronic Obstructive Pulmonary Disease Revenue (2019-2020) (Million US$)
Table 46. China Key Players Chronic Obstructive Pulmonary Disease Market Share (2019-2020)
Table 47. China Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020) (Million US$)
Table 48. China Chronic Obstructive Pulmonary Disease Market Share by Type (2015-2020)
Table 49. China Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020) (Million US$)
Table 50. China Chronic Obstructive Pulmonary Disease Market Share by Application (2015-2020)
Table 51. Japan Key Players Chronic Obstructive Pulmonary Disease Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Chronic Obstructive Pulmonary Disease Market Share (2019-2020)
Table 53. Japan Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Chronic Obstructive Pulmonary Disease Market Share by Type (2015-2020)
Table 55. Japan Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Chronic Obstructive Pulmonary Disease Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Chronic Obstructive Pulmonary Disease Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Chronic Obstructive Pulmonary Disease Market Share (2019-2020)
Table 59. Southeast Asia Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Chronic Obstructive Pulmonary Disease Market Share by Type (2015-2020)
Table 61. Southeast Asia Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Chronic Obstructive Pulmonary Disease Market Share by Application (2015-2020)
Table 63. India Key Players Chronic Obstructive Pulmonary Disease Revenue (2019-2020) (Million US$)
Table 64. India Key Players Chronic Obstructive Pulmonary Disease Market Share (2019-2020)
Table 65. India Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020) (Million US$)
Table 66. India Chronic Obstructive Pulmonary Disease Market Share by Type (2015-2020)
Table 67. India Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020) (Million US$)
Table 68. India Chronic Obstructive Pulmonary Disease Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Chronic Obstructive Pulmonary Disease Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Chronic Obstructive Pulmonary Disease Market Share (2019-2020)
Table 71. Central & South America Chronic Obstructive Pulmonary Disease Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Chronic Obstructive Pulmonary Disease Market Share by Type (2015-2020)
Table 73. Central & South America Chronic Obstructive Pulmonary Disease Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Chronic Obstructive Pulmonary Disease Market Share by Application (2015-2020)
Table 75. AstraZeneca Company Details
Table 76. AstraZeneca Business Overview
Table 77. AstraZeneca Product
Table 78. AstraZeneca Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020) (Million US$)
Table 79. AstraZeneca Recent Development
Table 80. GSK Company Details
Table 81. GSK Business Overview
Table 82. GSK Product
Table 83. GSK Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020) (Million US$)
Table 84. GSK Recent Development
Table 85. MSD Company Details
Table 86. MSD Business Overview
Table 87. MSD Product
Table 88. MSD Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020) (Million US$)
Table 89. MSD Recent Development
Table 90. Sunovion Company Details
Table 91. Sunovion Business Overview
Table 92. Sunovion Product
Table 93. Sunovion Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020) (Million US$)
Table 94. Sunovion Recent Development
Table 95. Novartis Company Details
Table 96. Novartis Business Overview
Table 97. Novartis Product
Table 98. Novartis Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020) (Million US$)
Table 99. Novartis Recent Development
Table 100. Roche Group Company Details
Table 101. Roche Group Business Overview
Table 102. Roche Group Product
Table 103. Roche Group Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020) (Million US$)
Table 104. Roche Group Recent Development
Table 105. Pfizer Company Details
Table 106. Pfizer Business Overview
Table 107. Pfizer Product
Table 108. Pfizer Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020) (Million US$)
Table 109. Pfizer Recent Development
Table 110. Jubilant Pharma Limited Business Overview
Table 111. Jubilant Pharma Limited Product
Table 112. Jubilant Pharma Limited Company Details
Table 113. Jubilant Pharma Limited Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020) (Million US$)
Table 114. Jubilant Pharma Limited Recent Development
Table 115. Almirall Company Details
Table 116. Almirall Business Overview
Table 117. Almirall Product
Table 118. Almirall Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020) (Million US$)
Table 119. Almirall Recent Development
Table 120. Horizon Pharma Company Details
Table 121. Horizon Pharma Business Overview
Table 122. Horizon Pharma Product
Table 123. Horizon Pharma Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020) (Million US$)
Table 124. Horizon Pharma Recent Development
Table 125. Boehringer Ingelheim Company Details
Table 126. Boehringer Ingelheim Business Overview
Table 127. Boehringer Ingelheim Product
Table 128. Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disease Business (2015-2020) (Million US$)
Table 129. Boehringer Ingelheim Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Obstructive Pulmonary Disease Market Share by Type: 2020 VS 2026
Figure 2. Bronchodilators Features
Figure 3. Glucocorticoids Features
Figure 4. Other Features
Figure 5. Global Chronic Obstructive Pulmonary Disease Market Share by Application: 2020 VS 2026
Figure 6. Prevention Case Studies
Figure 7. Diagnostic Case Studies
Figure 8. Treatment Case Studies
Figure 9. Chronic Obstructive Pulmonary Disease Report Years Considered
Figure 10. Global Chronic Obstructive Pulmonary Disease Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Chronic Obstructive Pulmonary Disease Market Share by Regions: 2020 VS 2026
Figure 12. Global Chronic Obstructive Pulmonary Disease Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Chronic Obstructive Pulmonary Disease Market Share by Players in 2019
Figure 15. Global Top Chronic Obstructive Pulmonary Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Obstructive Pulmonary Disease as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Chronic Obstructive Pulmonary Disease Revenue in 2019
Figure 17. North America Chronic Obstructive Pulmonary Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Chronic Obstructive Pulmonary Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Chronic Obstructive Pulmonary Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Chronic Obstructive Pulmonary Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Chronic Obstructive Pulmonary Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Chronic Obstructive Pulmonary Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Chronic Obstructive Pulmonary Disease Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
慢性閉塞性肺疾患治療の世界市場（～2026年） Market Analysis and Insights: Global Chronic Obstructive Pulmonary Disease Treatment Market The global Chronic Obstructive Pulmonary Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Chronic Obstructive…- 慢性血栓塞栓性肺高血圧症（CTEPH）の世界市場（～2026年） Chronic thromboembolic pulmonary hypertension is observed to be one of the leading causes of severe pulmonary hypertension. It is a type of clinical condition in which pulmonary vascular resistance increases giving rise to pulmonary hypertension and progressive heart failure. According to World Heal…
- 慢性腎臓病（CKD）の世界市場（～2026年） Market Analysis and Insights: Global Chronic Kidney Disease (CKD) Market The global Chronic Kidney Disease (CKD) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Chronic Kidney Disease (CKD) Scope and Market Size Chroni…
- 肺ドラッグデリバリーシステム（PDDS）の世界市場（～2026年） Market Analysis and Insights: Global Pulmonary Drug Delivery System (PDDS) Market The global Pulmonary Drug Delivery System (PDDS) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Pulmonary Drug Delivery System (PDDS) S…
- 慢性肺疾患治療の世界市場（～2026年） Lung disease is a very common medical condition that is present in almost every region of the world. Chronic lung diseases can be dangerous and if not treated properly can cause death. The chronic lung diseases cause uneasiness and complications in the respiratory system thus causing difficulty in r…